Cis-9,trans-11-CLA exerts anti-inflammatory effects in human bronchial epithelial cells and eosinophils: comparison to trans-10,cis-12-CLA and to linoleic acid

Biochim Biophys Acta. 2005 Dec 15;1737(2-3):111-8. doi: 10.1016/j.bbalip.2005.11.001. Epub 2005 Nov 9.

Abstract

Interaction of eosinophils and bronchial epithelial cells plays a pivotal role in maintaining inflammatory airway disease. Since conjugated linoleic acids (CLA) are suggested to exert anti-inflammatory effects, one purpose of this study was to compare cis-9,trans-11-CLA and trans-10,cis-12-CLA with regard to their influence on the stimulus-induced activation of eosinophils. ECP (eosinophil cationic protein) released in co-culture of stimulated and CLA-treated eosinophils with stimulated bronchial epithelial cells (BEAS-2B) was measured and cis-9,trans-11-CLA was found to be most potent in inhibiting ECP formation. Further, expression of the activation markers CD69 and CD13 induced by various stimuli (TNF-alpha, IL-5, IL-3) was significantly reduced in the presence of cis-9,trans-11-CLA. Subsequently, various concentrations of cis-9,trans-11-CLA vs. linoleic acid (LA, cis-9,cis-12-octadecadienoic acid) were tested for the effect on proliferative response and release of the pro-inflammatory cytokine IL-8 in stimulated BEAS-2B. Addition of cis-9,trans-11-CLA attenuated cell growth and significantly reduced IL-8 production at mRNA and protein levels. In contrast, LA had a slight stimulating effect on proliferation and was less effective in reducing the cytokine release. It was demonstrated that the inhibitory effect of cis-9,trans-11-CLA on IL-8 production is mediated through activation of the nuclear receptor PPARgamma, since blocking the receptor with a selective antagonist (GW9662) restored the stimulus-induced enhancement in IL-8 mRNA expression and protein secretion. PPARgamma has previously been shown to be closely involved in the downregulation of inflammation during hyperresponsiveness related to pulmonary immune responses. Thus, targeting PPARgamma, cis-9,trans-11-CLA might be of therapeutic value in the focus of airway disease while ameliorating inflammatory processes by affecting epithelial and eosinophil functions.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Antigens, CD / metabolism
  • Antigens, Differentiation, T-Lymphocyte / metabolism
  • Base Sequence
  • Bronchi / cytology
  • Bronchi / drug effects*
  • Bronchi / immunology
  • CD13 Antigens / metabolism
  • Cell Line
  • Cell Proliferation / drug effects
  • Eosinophil Cationic Protein / biosynthesis
  • Eosinophils / drug effects*
  • Eosinophils / immunology
  • Epithelial Cells / drug effects
  • Epithelial Cells / immunology
  • Humans
  • Interleukin-8 / biosynthesis
  • Interleukin-8 / genetics
  • Lectins, C-Type
  • Linoleic Acid / pharmacology*
  • Linoleic Acids, Conjugated / chemistry
  • Linoleic Acids, Conjugated / pharmacology*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Stereoisomerism

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antigens, CD
  • Antigens, Differentiation, T-Lymphocyte
  • CD69 antigen
  • Interleukin-8
  • Lectins, C-Type
  • Linoleic Acids, Conjugated
  • RNA, Messenger
  • cis-9, trans-11-conjugated linoleic acid
  • trans-10,cis-12-conjugated linoleic acid
  • Linoleic Acid
  • Eosinophil Cationic Protein
  • RNASE3 protein, human
  • CD13 Antigens